KIT and chronic myelogenous leukemia, BCR-ABL1 positive: In recent years, Imatinib has been a marketed effective drug for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) [3], and the two listed disorders are caused by BCR-ABL and c-kit oncogenes [4], respectively.